Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery (NCT06880835)
INHALE-AIDEx: A Randomized Crossover Trial Evaluating the Effect of Inhaled Technosphere Insulin (Afrezza®) vs Rapid Acting Analogue Insulin on Exercise-Induced Hypoglycemia in Adults With Type 1 Diabetes Using Automated Insulin Delivery
🩺 Plain-English Summary (8th-Grade Level)
This investigator-initiated study will enroll about 30 adults 18 to 65 years of age with type 1 diabetes (T1D) who are using the Tandem t:slim X2 insulin pump or Tandem Mobi insulin pump with Control-IQ or Control-IQ+ technology ("Control-IQ" which will refer to either Control-IQ or Control-IQ+). The study is being done to find out if inhaled insulin given for a meal is safer and better to use than a bolus of insulin through your pump when you exercise following a meal. Participants are asked to complete three study exercise visits in the clinic.
Who can join: Review the eligibility criteria below.
Location: University of Louisville — Louisville, Kentucky
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- University of Louisville — Louisville, Kentucky
- University of Pennsylvania — Philadelphia, Pennsylvania
- University of Washington — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (813) 975-8690
Email: rgal@jaeb.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diabetes Mellitus, Type 1
- Testing an Integrated Care Model Trial — Atlanta, Georgia
- Safety of ENC-201-CED ENCRT — Toronto, Ontario
- Teplizumab in Pediatric Stage 2 Type 1 Diabetes — San Francisco, California
- Allogenic Islet Cell Transplantation — Chicago, Illinois
- Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells — Charleston, South Carolina
- Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes — Stanford, California
Explore by condition: All Diabetes Mellitus, Type 1 clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.